BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics
Reuters
Feb 12
BRIEF-Aprea Therapeutics Strengthens Global Patent Portfolio In Dna Damage Response (Ddr) Cancer Therapeutics
Feb 12 (Reuters) - Aprea Therapeutics Inc APRE.O:
APREA THERAPEUTICS STRENGTHENS GLOBAL PATENT PORTFOLIO IN DNA DAMAGE RESPONSE (DDR) CANCER THERAPEUTICS, PAVING WAY FOR PIPELINE GROWTH
APREA THERAPEUTICS INC - GRANTED NEW PATENTS IN AUSTRALIA AND JAPAN
APREA THERAPEUTICS INC - CORE PATENT FAMILIES EXPECTED TO PROVIDE EXCLUSIVITY INTO 2045
APREA THERAPEUTICS INC - EXISTING ISSUED PATENTS EXPECTED TO REMAIN IN FORCE THROUGH 2035-2037
Source text: ID:nGNX7Tpb4K
Further company coverage: APRE.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.